FDMT
Price:
$15.07
Market Cap:
$783.18M
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular deg...[Read more]
Industry
Biotechnology
IPO Date
2020-12-11
Stock Exchange
NASDAQ
Ticker
FDMT
According to 4D Molecular Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -6.79. This represents a change of -30.53% compared to the average of -9.77 of the last 4 quarters.
The mean historical PE Ratio of 4D Molecular Therapeutics, Inc. over the last ten years is -24.33. The current -6.79 PE Ratio has changed 2.69% with respect to the historical average. Over the past ten years (40 quarters), FDMT's PE Ratio was at its highest in in the June 2022 quarter at -2.06. The PE Ratio was at its lowest in in the September 2020 quarter at -27.91.
Average
-24.33
Median
-19.56
Minimum
-53.54
Maximum
-7.11
Discovering the peaks and valleys of 4D Molecular Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 10.60%
Maximum Annual PE Ratio = -7.11
Minimum Annual Increase = -61.82%
Minimum Annual PE Ratio = -53.54
Year | PE Ratio | Change |
---|---|---|
2023 | -7.86 | 10.60% |
2022 | -7.11 | -20.20% |
2021 | -8.91 | -54.46% |
2020 | -19.56 | -3.49% |
2019 | -20.27 | -61.82% |
2018 | -53.08 | -0.85% |
The current PE Ratio of 4D Molecular Therapeutics, Inc. (FDMT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-7.96
5-year avg
-12.74
10-year avg
-24.33
4D Molecular Therapeutics, Inc.’s PE Ratio is less than TCR2 Therapeutics Inc. (-0.44), greater than Revolution Medicines, Inc. (-13.31), less than Black Diamond Therapeutics, Inc. (-3.70), less than Atreca, Inc. (-0.04), less than Passage Bio, Inc. (-0.57), less than Century Therapeutics, Inc. (-0.91), greater than Edgewise Therapeutics, Inc. (-14.14), less than C4 Therapeutics, Inc. (-3.44), less than Mineralys Therapeutics, Inc. (-4.63), greater than Cullinan Oncology, Inc. (-6.96), less than Biomea Fusion, Inc. (-1.83), greater than Stoke Therapeutics, Inc. (-7.92), greater than Akero Therapeutics, Inc. (-8.95), less than Homology Medicines, Inc. (-0.01), less than Gossamer Bio, Inc. (-2.55), less than Replimune Group, Inc. (-3.26), less than Nuvectis Pharma, Inc. (-4.95), less than Lyra Therapeutics, Inc. (-0.18), less than Kronos Bio, Inc. (-0.58),
Company | PE Ratio | Market cap |
---|---|---|
-0.44 | $58.11M | |
-13.31 | $6.99B | |
-3.70 | $305.13M | |
-0.04 | $3.57M | |
-0.57 | $43.48M | |
-0.91 | $123.69M | |
-14.14 | $1.64B | |
-3.44 | $374.42M | |
-4.63 | $558.43M | |
-6.96 | $1.04B | |
-1.83 | $256.37M | |
-7.92 | $773.92M | |
-8.95 | $1.83B | |
-0.01 | $3.02M | |
-2.55 | $205.87M | |
-3.26 | $708.49M | |
-4.95 | $115.27M | |
-0.18 | $17.85M | |
-0.58 | $59.36M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like 4D Molecular Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like 4D Molecular Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is 4D Molecular Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for 4D Molecular Therapeutics, Inc. (FDMT)?
What is the highest PE Ratio for 4D Molecular Therapeutics, Inc. (FDMT)?
What is the 3-year average PE Ratio for 4D Molecular Therapeutics, Inc. (FDMT)?
What is the 5-year average PE Ratio for 4D Molecular Therapeutics, Inc. (FDMT)?
How does the current PE Ratio for 4D Molecular Therapeutics, Inc. (FDMT) compare to its historical average?